Immunocore’s T-Cell Cancer Vaccine Moves into Phase IIa
By Nuala Moran
Wednesday, October 30, 2013
LONDON – Immunocore Ltd. has opened a Phase IIa trial of its T-cell cancer vaccine, IMGgp100, after demonstrating immune responses and evidence of tumor shrinkage in some of the 31 patients with late-stage melanoma who took part in the Phase I single-dose study.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.